Your medical cost
doesn’t start at the claim.
It starts months earlier, in a visit where the diagnosis didn’t arrive on time. That’s where we work, with the physicians already in your network.
It isn’t in the visit. It’s in the episode that escalated.
$122,278 million pesos
paid out in medical claims.
Four figures from independent sources. Chained, they explain why the spend grows and where it can be interrupted.
growth in medical claims paid over five years.
of that payout is hospitalisation, not consultation.
of cases that escalated to intensive care or death: missed or delayed diagnosis.
is diagnostic accuracy by the sixth hour of a shift.
That’s where DeepClinic works: it holds accuracy inside the visit, with the full history in front. And it is priced against avoided cost, measured in the same record that produced it.
Your medical cost is decided in this room. The claim only bills it, months later.
The cost is decided
at four moments.
Reason and urgency classified before the appointment.
The full history in front of the physician. The note writes itself.
Medication and tests reminded between visits.
ICD-10 with justification cited from the note.
What you see today as loose claims, here reads as episodes.
All of it on the providers you already contract. No implementation on your side.
Triage decides where the patient goes. We decide what happens once they’re there.
We don’t compete: we start where triage ends.
Infermedica reports 27% fewer in-person visits in Latin America: the category already sells. Our unit isn’t the interaction — it’s the episode.
The same claim, with the evidence inside it.
What is settled today by sending paperwork back. Drag the divider to compare how it gets solved today against how it ends up.
Arrives incomplete and is sent back twice.
Complete, with the code already validated.
Days of back and forth by phone and email.
Evidence attached from the start.
Audited on scanned paper.
Traceable to the note that ordered it.
Each physician documents however they can.
One standard across the network.
Visible at the quarterly close.
Visible while it is happening.
Each card shows both sides. Drag the divider to light up one or the other.
A country’s public network
already runs on this layer.
An entire country’s public health system sees patients with DeepClinic inside the visit. Not a pilot: the whole network.
Our own measurement against that system’s historical baseline. The effect on admissions is not measured there: that is what we propose measuring on your book.
See the four stepsMove the three factors.
What comes out is your avoidable cost.
Three steps and none of them ours: what you pay out, how much goes to hospitalisation, and how much of that starts with a late diagnosis.
Mexican market: $122,278M in 2024 · AMIS
Mexican market average · AMIS 2024
The hypothesis. JAMA: 23% of cases that escalated. The default is conservative.
A hypothesis, not a promise. The only number that counts is yours, and it comes from running a year of your claims against your own baseline.
From a claims export
to the first wave, with no budget.
No implementation on your side. Providers go live in waves: each is its own control.
Code, amount, date and provider. NDA signed before we receive it.
Duplicate testing, repeat visits and late-diagnosis escalation, quantified.
Your codes, your history and the wave activation calendar. Signed before we start.
No install, no change to your system and no work for your team.
It is priced against avoided cost.
A share of the saving measured in the same record that produced it, against the baseline signed before we start. If the effect doesn’t show up, there is nothing to charge.
- No per-member licence
- No implementation fee
- Billed on verified savings
Member data
never changes hands.
LFPDPPP and HIPAA. We never train on one client’s records to serve another.
The whole episode in HL7 FHIR, with provenance and signature. Your audit stops asking for paperwork.
DeepClinic gathers the evidence and reasons the case; it never decides and never signs.
What any claims director would ask.
Answered here instead of in the meeting, because these are the ones that decide whether this is a purchase or just another presentation.
Because it is never measured against a market average, but against your own baseline and with wave-based activation. The methodology is above, under “How it is measured”. If the effect doesn’t show up, there is no saving to charge for.
Because we don’t add work, we remove it. The note, the diagnosis code and the prescription come out while they talk to the patient, and the claim is born from that same record, so fewer get denied. They don’t change systems and install nothing. Without that incentive on the physician’s side there is no adoption, and without adoption there is no saving.
No, it feeds it. Today you audit a sample and request paperwork; with DeepClinic the whole episode sits in HL7 FHIR, with the provenance of every suggestion and the signature of whoever accepted it. Your team stops reconstructing records and starts reviewing the cases that matter.
The physician, always. DeepClinic gathers the evidence, reasons the case and traces every suggestion; it never decides and never signs. Clinical liability does not move from where it sits today, and that is deliberate.
For the analysis, an export of one year of claims: no implementation, no budget. For activation, providers in your network who already see your members. Your adjudication system is never touched.
It is encrypted and isolated per provider, under Mexico’s data protection law (LFPDPPP) and HIPAA when data crosses into the United States. We do not train models on one client’s records to serve another, and every access lives in an auditable log.
Where every number on this page comes from.
$122,278M paid out in medical claims in 2024, up 106% in five years. 65.2% is hospitalisation.
23% of those who escalated to intensive care or died: missed or delayed diagnosis.
Medical cost rises 10.3% globally in 2026. Latin America accelerates to 11.9%.
Roughly one in five dollars of health spending goes to avoidable or low-value care (ACSC).
27% fewer in-person visits with digital triage in Latin America. Market reference, not our own result.
96.1% against a 55% baseline, across 2 million consultations in a country’s public system.
What is not measured: the effect on the hospitalisation rate. It does not exist in our data and we do not claim it. It is what we propose measuring on your book.
Your medical cost,
measured where it is generated.
We start by analysing a year of your claims, with no commitment: we show you duplicate testing, repeat visits for the same reason and escalation from late diagnosis across your own book.